Blue Jet Healthcare reports strong FY25 financial performance

Blue Jet Healthcare Limited reported a significant 44.74% year-on-year increase in revenue from operations, reaching ₹10,299.85 million for FY2025. This growth was primarily fueled by a 387.75% surge in sales of pharma intermediates and APIs to ₹4,622.07 million, alongside a 4.10% rise in artificial sweeteners sales to ₹1,335.06 million. The company's net profit after tax grew by 86.38% to ₹3,052.03 million, leading to an EPS of ₹17.59. EBITDA also saw a substantial increase of 64.78% to ₹3,777.30 million, with a margin of 36.67%.

Operationally, FY2025 was a defining year, marked by the commissioning of Plant 6 at Unit II, Ambernath, adding 157 KL of new capacity for pharma intermediates and contrast media products. The company commercialized a gadolinium-based contrast media intermediate and committed ₹400 million to a new R&D center. Blue Jet Healthcare's balance sheet remains debt-free, and it declared a final dividend of ₹1.20 per equity share.